674 related articles for article (PubMed ID: 34288015)
21. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
[TBL] [Abstract][Full Text] [Related]
22. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
23. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
24. The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH.
Sountoulides P; Gravas S
Curr Drug Targets; 2015; 16(11):1172-9. PubMed ID: 25706255
[TBL] [Abstract][Full Text] [Related]
25. A review of combination therapy in patients with benign prostatic hyperplasia.
McVary KT
Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
[TBL] [Abstract][Full Text] [Related]
26. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
De Nunzio C; Salonia A; Gacci M; Ficarra V
World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
[TBL] [Abstract][Full Text] [Related]
27. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.
Pang R; Zhou XY; Wang X; Wang B; Yin XL; Bo H; Jung JH
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012336. PubMed ID: 33567116
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
29. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
30. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
31. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.
Lin-Tsai O; Clark PE; Miller NL; Fowke JH; Hameed O; Hayward SW; Strand DW
Prostate; 2014 May; 74(6):669-79. PubMed ID: 24500928
[TBL] [Abstract][Full Text] [Related]
32. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
[TBL] [Abstract][Full Text] [Related]
33. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
Kogan MI; Avadieva NE; Gevorkyan LS; Loginov YA; Metelkin AM; Mitin AA; Patrikeev AA
Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
[TBL] [Abstract][Full Text] [Related]
34. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
[TBL] [Abstract][Full Text] [Related]
35. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
36. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
Lepor H
Urol Clin North Am; 2016 Aug; 43(3):311-23. PubMed ID: 27476124
[TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis.
Wang X; Wang X; Li S; Meng Z; Liu T; Zhang X
PLoS One; 2014; 9(9):e107593. PubMed ID: 25216271
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacological treatment of benign prostatic hyperplasia].
Oelke M; Kuczyk MA; Herrmann TR
Urologe A; 2009 Nov; 48(11):1365-75; quiz 1376-7. PubMed ID: 19851747
[TBL] [Abstract][Full Text] [Related]
40. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015.
Schauer I; Madersbacher S
Curr Opin Urol; 2015 Jan; 25(1):6-11. PubMed ID: 25393269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
